Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Impulsivity: early-phase trial registry

2 of 5 indexed Impulsivity trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Impulsivity: 5 US clinical trials tracked, 2 recruiting.

Impulsivity is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 2 of these trials.

Enrollment posture brief

Registry condition impulsivity

OPEN 2 | RECR 40% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Impulsivity (this)40%
Open-enrollment share among volume-matched conditions near Impulsivity

Impulsivity lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Impulsivity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Impulsivity is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Impulsivity research.

    VA Office of Research and Development accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Impulsivity trials plan to enrol fewer than 100 people.

    Median target enrolment is 33 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. Impulsivity research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Impulsivity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Active Transcranial Direct Current Stimulation (tDCS) Device
2 trials
Sham Transcranial Direct Current Stimulation (tDCS) Device
2 trials
Phospholean Dietary supplement
1 trials
placebo intermittent theta burst stimulation Device
1 trials
intermittent theta burst stimulation Device
1 trials
Shaping Delay Tolerance Behavioral
1 trials
Placebo Dietary supplement
1 trials

US sites by state

Facility locations filed on Impulsivity trials. A trial with sites in several states counts in each.

Minnesota 2 trials
Illinois 1 trials
Connecticut 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Impulsivity page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Impulsivity condition card totals 5 registered trials; most-linked intervention Active Transcranial Direct Current Stimulation (tDCS); top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.